GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » 5-Year Yield-on-Cost %

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) 5-Year Yield-on-Cost % : 0.00 (As of May. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings 5-Year Yield-on-Cost %?

Coeptis Therapeutics Holdings's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Coeptis Therapeutics Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:



COEP's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.615
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Coeptis Therapeutics Holdings's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coeptis Therapeutics Holdings's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's 5-Year Yield-on-Cost % falls into.



Coeptis Therapeutics Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Coeptis Therapeutics Holdings is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Coeptis Therapeutics Holdings  (NAS:COEP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Coeptis Therapeutics Holdings 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Executives
Tara Desilva director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick director, 10 percent owner, officer: CEO and President 5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind director 1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace director, officer: VP of Operations 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise director, 10 percent owner, officer: Chief Financial Officer 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps director 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy officer: CFO and Secretary 206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc 10 percent owner 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr. 10 percent owner 151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp 10 percent owner 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Headlines